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Abstract 
With the rapid growth of trade, commerce and industries, the numbers of publicly traded companies are 
considerably increasing in Bangladesh. Pharmaceutical is an important adjunct of industrialization in the country. 
But the net profit of this industry has decreased for the last few years. This paper attempted to review the financial 
performance of this industry, to test its strengths and weaknesses. This study is based on both primary and secondary 
data. The collected data have been tabulated, analyzed and interpreted with the help of different financial ratios, 
Multivariate Discriminate Analysis (MDA) as developed by Prof. Altman and statistical tools like mean, standard 
deviation (SD), coefficient of variance (CV) and T-test, etc. It was observed from the study of the financial 
statement of the Pharmaceutical industry that the profit earning capacity, liquidity position, financial position and 
the performance of the most of the Pharmaceuticals are not in sound position and it was also observed that the most 
of the Pharmaceuticals has a lower level position of bankruptcy. The reasons behind this position of the industry are 
inefficiency of financial management, absence of realistic goals, strict government regulation and increased cost of 
raw-materials, labor and overhead. The financial performance should be improved immediately. Therefore, the 
appropriate authority should take measures for the removal of the above problems. 
Keywords: Financial Performance, Ratio Analysis, Pharmaceuticals Industry, Multivariate Discriminate Analysis 
(MDA), T-test. 
 
1. Introduction  
Financial analysis is the process of identifying the financial strengths and weaknesses of the firm by properly 
establishing relationship between the items of the balance sheet and the profit and loss account Pandey (1979). 
Financial Statements (income statement, cash flow statement, owners’ equity statement and balance sheet) contain a 
wealth of information which, if properly analyzed and interpreted, can provide valuable insights into a firm’s 
performance and position. Performance measurement of public enterprises has been the subject matter of discussion 
for planners, administrators, managers, economists and academics since long. But some lack of clarity about 
performance and the existence of defensive attitude on the part of those who have to take responsibility for 
inefficient operations have the effect of inhibiting both frame discussion and decisive action in this regard Bunnett 
(1987). Analysis of financial statements is of interest to lenders, security analysts, managers and others Prasanna 
(1995). Trade creditors are interested in the firm’s ability to meet their claims. Their analysis will therefore, confine 
to the evaluation of the firm’s liquidity position. The suppliers are concerned with the firm’s solvency and survival. 
They analyze the firm’s profitability over time. Long term creditors place more emphasis on the firm’s solvency and 
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profitability. The investors are most concerned about the firm’s earnings. So, they concentrate on the analysis of the 
firm’s present and future profitability as well as earning ability and risk Abu Sina and Arshed Ali (1998). Publicly 
traded companies are the economic pulse of a nation. Their birth, prosperity and demise generally reflect the 
financial condition of the country. A fairly reliable index of an economy in its process of growth and development is 
the rate of growth and decline of publicly traded companies. With the rapid growth of trade, commerce and 
industries, the numbers of publicly traded companies are considerably increasing in Bangladesh. Pharmaceutical is 
an important adjunct of industrialization in the country. There are 20 listed Pharmaceutical Companies in Dhaka 
Stock Exchange and 16 listed in Chittagong Stock Exchange. Analyzing the Industrial Life Cycle, it has been found 
that all of the listed companies have just reached the middle stage. No company could reach the maturity stage. In a 
word, the Pharmaceutical industry of the country is just improving.  It is well known that the Pharmaceuticals 
industry is one of the key to earning foreign currency. On the other hand, most of the internal demand for drugs is 
fulfilled by the domestic Pharmaceutical industry of the country. But this industry of Bangladesh depends on foreign 
country for raw-material and technology. Now the time to make the Pharmaceutical firms self sufficient for the 
betterment of the country. At this time, performance of manufacturing enterprise, like Pharmaceutical, needs to be 
measured and analyzed. But evaluation of performance is not a regular practice in the country. Against this backdrop 
this study is an attempt to evaluate performance of some selected Pharmaceuticals for the period under study.  
2. Objectives of the study 
The study is designed to achieve the following objectives: 
(i)  To assess the financial performance of the selected Pharmaceuticals firms. 
(ii)  To examine the financial state of affairs of the selected Pharmaceuticals firms. 
(iii)  To test the financial strengths and weaknesses of selected Pharmaceuticals firms. 
(iv)  To pinpoint the causes of poor financial performance and suggest some measures to overcome the problems. 
 
3. Hypothesis 
The research is based on following hypothesis. 
H0: There is no significant difference between the industry mean and the individual firm’s ratio. 
H1: There is significant difference between the industry mean and the individual firm’s ratio. 
4. Methodology of the study 
Data has been taken from a sample of 9 Pharmaceuticals in Bangladesh. For the study only A and B category 
Pharmaceuticals are considered. “A” category Pharmaceutical includes those Pharmaceuticals that hold annual 
general meeting (AGM) and declare minimum 10% dividend regularly. The trading time of “A” category 
Pharmaceutical’s share is T+3. “B” category Pharmaceutical includes those Pharmaceuticals that hold annual 
general meeting (AGM) regularly but declare dividend at a rate below 10% on a regular basis. The trading time of 
“B” category Pharmaceutical’s share is also T+3. “Z” category Pharmaceutical includes those Pharmaceuticals that 
neither hold annual general meeting (AGM) nor declare dividend on a regular basis. The trading time of “Z” 
category Pharmaceutical’s share is T+7. Moreover, the size of the Pharmaceuticals, availability of information, and 
year of establishment are also considered for selecting the Pharmaceuticals. The study covers a three year period 
from 2005-06 to 2007-08. This study is based on both primary and secondary data. Secondary data are the annual 
reports of the selected Pharmaceuticals firms and various studies made available through library work. The primary 
data was collected through personal interview and discussions with the concerned executives of the selected 
Pharmaceuticals firms.  
The collected data have been tabulated, analyzed and interpreted with the help of different financial ratios, 
Multivariate Discriminate Analysis (MDA) as developed by Prof. Altman and statistical tools like mean, standard 
deviation (SD), coefficient of variance (CV) and T- test, etc. The hypothesis has been tested statistically to arrive at 
conclusion and policy implication.   
5. Literature Review 
Financial ratios are the simplest tools for evaluating the financial performance of the firm Wen-Cheng LIN et. al 
(2005). One can employ financial ratios to determine a firm’s liquidity, profitability, solvency, capital structure and 
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assets turnover. Hannan and Shaheed (1979) used financial ratios to show the financial position and performance 
analysis of Bangladesh Shilpa Bank. He showed that techniques of financial analysis can be used in the evaluation 
of financial position and performance of financial institution as well as non financial institutions even Development 
Financial Institutions (DFI). Altman (1968) used financial ratios to predict corporate bankruptcy. He found that the 
bankruptcy model has an accuracy rate of 93% and is very successful in predicting failed and non-failed firms. Sina 
and Arshed Ali (1998) used financial ratios to test the financial strengths and weaknesses of Khulna Newsprint Mills 
Ltd. He found that due to lack of planning and control of working capital, operational inefficiency, obsolete store, 
ineffective credit policy, increased cost of raw materials, labor and overhead, the position of the company was not 
good. Saleh Jahur and Mohi Uddin (1995) used financial ratios to measure operational performance of limited 
company. They used profitability, liquidity, activity and capital structure to measure operational performance. Saleh 
Jahur and Parveen (1996) used Altman’s MDA model to conclude the bankruptcy position of Chittagong Steel Mills 
Ltd. They found that absences of realistic goals, strict govt. regulation are the main reasons for the lowest level of 
bankruptcy. Ohlson (1980) employed financial ratios to predict a firm’s crisis. He found that there are four factors 
affecting a firm’s vulnerability. These factors are the firm’s scale, financial structure, performance and liquidity.  
In the article “The Assessment of Financial and Operating Performance of the Cement Industry: A Case Study of 
Confidence Cement Limited”, Dutta and Bhattacharjee (2001) found that the investment in cement was fairly 
profitable. Salauddin (2001) examined the profitability of the Pharmaceutical Companies of Bangladesh. By using 
ratio analysis, mean, standard deviation and co-efficient of variation he found that the profitability of the 
Pharmaceuticals sector was very satisfactory in terms of the standard norms of return on investment. Hye & Rahman 
(1997) conducted a research to assess the performance of the selected private sector general insurance companies in 
Bangladesh. The study revealed that the private sector insurance companies had made substantial progress. The 
study found that the insurance companies were keeping their surplus funds in the form of fixed deposits with 
different commercial banks due to absence of suitable avenues for investment. These studies attest that the ratio 
analysis and MDA are the good method to evaluate firm performance. The researcher uses these tools to measure the 
financial performance of 9 selected Pharmaceutical firms in this paper. 
 
6. Theoretical discussion of Financial Ratio 
Financial analysis offers a system of appraisal and evaluation of a firm’s performance and operations; it is the 
analysis of the financial statement of an enterprise. The analysis of financial statement can be best done by various 
yardsticks of which, the important is known as ratio or percentage analysis. Ratio is a numerical or an arithmetical 
relation between two figures. It is expressed when one figure is divided by another. Accounting ratios show inter-
relationship which exist among various accounting data. Accounting ratio can be expressed in various ways such as, 
a pure ratio, a rate or a percentage. Ratio analysis is certainly a very admirable device because it is simple and it has 
a predictive value. Management and other users thus, rely substantially on the financial ratios based on accounting 
data for making assessments and predictions of past performance, present position and probable future potentials. 
One important way for diagnosing the financial health is to measure the profitability, liquidity, activity and solvency 
and the level of the bankruptcy of enterprise. 
6.1 Profitability Ratio 
Profitability is a measure of efficiency. It also indicates public acceptance of the product and shows that the firm can 
produce competitively. The profitability ratios measure the performance of profit of an enterprise. In other words the 
profitability ratios are designed to provide answers to questions such as what is the rate of profit?. What is EPS? 
What is the rate of investment? What is the rate of equity? Is the profit earned by the enterprise adequate? What is 
the dividend payout ratio? What is retention ratio and so on? The analysis of the profitability ratio is important for 
the shareholders, creditors, prospective investors, bankers and the government alike. Gross profit margin ratio, 
return on investment, net profit margin ratio and operating profit ratio can be used to measure the liquidity position 
of the enterprise. 
6.2 Liquidity Ratio 
The liquidity ratios measure the ability of an enterprise to meet its short-term obligations and reflect the short-term 
financial strength of an enterprise. Liquidity is a pre-requisite for the very survival of an enterprise. Analysis of 
liquidity is very important in knowing the liquidity status, movement of funds, idle fund (if any) which will not only 
help financial management to keep the liquidity position of the company  in order but also make sure of payment to 
short-term creditors, interested in short-term solvency of the company. Liquidity ratios reveal the rate at which fixed 
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and working assets are being converted into cash and the time when the cash will be required. Current ratio, quick 
ratio and working capital to total asset ratio can be used to measure the liquidity position of the enterprise. 
6.3 Activity Ratio 
Activity ratios indicate the effectiveness of an enterprise with which different assets are managed and utilized in a 
business. The efficiency in assets management is measured by activity ratio which involves the comparisons 
between the level of sales and investment in various assets accounts, inventories, bill receivable, fixed assets and 
others. The activity can be measured by the use of activity ratios such as inventory turnover, fixed assets turnover 
and total assets turnover.  
6.4 Solvency Ratio 
The long-term solvency of a company is an important aspect to the present and future long-term creditors, banks, 
debenture holders etc. Before sanctioning loan or buying a debenture or preference share, they are interested to see 
whether the company has ability to pay the interest regularly as well as repay the installment of the principal on due 
date or in one lump sum at the time of maturity. The long-run solvency of a company can be measured by the use of 
solvency ratios named debt to total assets, the time interest earned and retained earning to total assets. 
7. Findings and Discussions 
7.1 Profitability Ratio 
The tables (01, 02,03,04,05 and 06) depict various financial ratios covering profitability of the selected 
Pharmaceuticals for the period under study. 
7.1.1 Gross Profit Margin 
The earnings in terms of sales can be assessed through the profit margin. The gross profit margin reflects the 
effectiveness of pricing policy and of production efficiency. Some authors consider that a profit margin ratio ranging 
from 20% to 30% has been considered as the standard norm for any industrial enterprise. The table-01 shows that 
BXPHARMA he highest average gross profit ratio over the study period. The average gross profit ratios range from 
highest 34.43% in BXPHARMA to lowest 9.42% in BEACONPHAR study is to found that the industry average 
gross profit ratio was 17.69% and the average gross profit ratio of all but five samples was below industry average. 
The co-efficient of variation of gross profit ratios of the samples reveals that the variation of gross profit over the 
years is negligible except two sample companies (SQURPHARMA and BXPHARMA) which speaks about the 
stability of gross profit earning of this sector. In view of standard, the gross profit margin of SQURPHARMA , 
IBNSINA, BXPHARMA, AMBEEPHA during the period was higher than standard norm and shown an increasing 
trend but the ratio for ACTIVEFINE, RENETA, BEACONPHAR, BXPHARMA , and PHARMAID was lower than 
the standard. The higher ratio indicates favorable purchasing and markup policies and the ability of management to 
develop sales volume and lower ratio indicates unfavorable purchasing and markup policies and the inability of 
management to develop sales volume. This ratio also indicates that the selected enterprise (SQURPHARMA, 
IBNSINA, BXPHARMA, and AMBEEPHA) seems to be in an advantage position to service in the face of falling 
sales prices, rising cost of production or decline demand for the product. From the calculated value of t it is seen that 
there is a significant difference in gross profit ratio between industry average and individual pharmaceuticals firms 
except SQURPHARMA and AMBEEPHA. 
7.1.2 Net Profit Margin 
The ratio reveals the overall profitability of the concern, that’s why it is very useful to the proprietors and 
prospective investors. It also indicates management efficiency in manufacturing, administrating and selling of the 
products. The table-02 shows that the net profit ratios range from highest 10.75% in SQURPHARMA to lowest 
13.36 %( negative) in BXPHARMA. SQURPHARMA earned the highest average net profit margin (10.75%) and 
industry average is 1.35%. The calculated ratios in table-02 are all very lower position except SQURPHARMA, 
IBNSINA, RENETA and PHARMAID. Lower position refers to the company’s failure to achieve satisfactory return 
on owners’ equity. It also indicates that the efficiency of the samples is very low in position. The position of 
BXPHARMA is negative. The co-efficient of variation of net profit ratios of the samples reveals that the variation of 
net profit over the years is negligible except two sample companies SQURPHARMA (and BXPHARMA) which 
speaks about the stability of net profit earning of this sector. Calculated values of t’ state that there is a significant 
difference in net profit ratio between industry average and 5 individual pharmaceuticals firms (IBNSINA, 
BXPHARMA, RENETA, BEACONPHAR and PHARMAID). 
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7.1.3 Return on Investment (ROI) 
This ratio measures the profitability of enterprise on total investment. The Planning Commission, Government of 
Bangladesh has declared that the entire existing project in the public sector would have to guarantee a fixed return to 
7.5% of the investment. This may be considered as the standard norm for the industrial enterprise. The table-03 
shows that the return on investment on an average for the period under study varies from maximum 19.48% in 
SQURPHARMA to minimum 0.70% in BPL and the industry average is 6.67% which is lower than the standard 
norm of 7.5% . The ratio for BXPHARMA is negative. It is seen from the table that ACTIVEFINE, BXPHARMA, 
RENETA, BEACONPHAR, PHARMAID and BPL have a low ratio as compared to the industry average and 
standard norm, which is indicative of poor earning in terms of investment, the return on investment for 
SQURPHARMA(24.38%), IBNSINA (14.39%) and AMBEEPHA (11.16%) should be considered as extremely 
satisfactory as they are more than the industry average ratio and as well as the standard norm and this ratios are 
indicative of very good profitability in terms of investment. ACTIVEFINE, BXPHARMA, RENETA, 
BEACONPHAR, PHARMAID and BPL show a declining trend which indicates the inefficiency of the business as a 
whole. The co-efficient of variation of return on investment ratios of the samples reveals that the variation of return 
on investment over the years is negligible except two sample companies (SQURPHARMA and AMBEEPHA) 
which speaks about the stability of return on investment of this sector. From the calculated value of t it is observed 
that there is a significant difference in return on investment between industry average and 4 individual 
pharmaceuticals firms (ACTIVEFINE, IBNSINA, PHARMAID and BPL). For other pharmaceuticals the difference 
is insignificant.  
7.1.4 Operating Profit Ratio 
Operating Profit refers to the profit of an enterprise, which is obtained after deducting all operating expenses from 
gross profit. This ratio establishes the relationship between operating profit and sales. The ratio indicates the portion 
remaining out of every taka worth of sales after all operating cost and expenses have been met. It represents the 
overall earnings of an enterprise and one can get a clear idea about the efficiency of an enterprise from its operating 
profit ratio. The higher the ratio, the better is the overall efficiency of the enterprise. Operating profit ratio ranging 
4% to 6% is considered norm for the purpose of comparison and control by some authors (Jain and Narang, Jahur, 
Hye). The table-04 shows that the average operating profit ratio of the sample pharmaceuticals ranges from highest 
29.02% in BXPHARMA to lowest 0.41% in BEACONPHAR. The industry average operating profit ratio is 10.72% 
and most of the companies (5 out of 9) failed to attain the average but most of the companies’(5 out of 9) operating 
profit ratio is more than standard. As to variation of operating profit over the years, it is revealed by the coefficient 
of variance that the variation ranges from 0.033% in BEACONPHAR to 29.259% in BXPHARMA. The coefficient 
of variance of 10.407% and 29.259% indicates inconsistency in the overall earnings of SQURPHARMA and 
BXPHARMA. The negligible variation of 0.631% in ACTIVEFINE, 2.126% in IBNSINA, 1.659% in RENETA, 
0.033% in BEACONPHAR, 3.553% in AMBEEPHA, 0.130% in PHARMAID and 0.520% in BPL indicate 
extremely desirable stability position. From the calculated value of t it is observed that there is a significant 
difference in operating profit ratio between industry average and almost all individual pharmaceuticals firms except 
SQURPHARMA. 
7.1.5 Return on Capital Employed 
The most independent ratio for assessment of profitability is the return on capital employed. It reflects the overall 
efficiency with which capital is used. Here, Capital Employed=Equity share capital + Preference share capital+ 
Undistributed profit+ Reserve and Surplus+ Long term Liabilities- Fictitious Assets. A rate of return ranging from 
11% to 12% on Capital employed may be considered as reasonable for a selected enterprise. The table-05 represents 
the return on capital employed ratio of the sample pharmaceuticals for the study period. The table shows that the 
average returns on capital employed ranges from 1.46% in BPL to 13.79% in SQURPHARMA and the average ratio 
is negative for BXPHARMA (-7.52%).  It appears from the table that the industry average return on capital 
employed is 3.59% which is not satisfactory in terms of the standard norm. It is seen from the table that only 
SQURPHARMA has a high ratio as compared with standard norm, IBNSINA, BEACONPHAR, AMBEEPHA and 
PHARMAID have a high ratio as compared to industry average. ACTIVEFINE, BXPHARMA, RENETA and BPL 
have a ratio lower than industry average, which is indicative of poor earning in terms of capital employed. It appears 
from the table that BXPHARMA has the highest variation (43.107%) and AMBEEPHA has the second highest 
variation (27.971%) as indicated by the coefficient of variation which indicates extremely instability in their 
earnings. The variation of this ratio for ACTIVEFINE (0.046%), SQURPHARMA (7.491%), IBNSINA (0.946%), 
European Journal of Business and Management   www.iiste.org 
ISSN 2222-1905 (Paper) ISSN 2222-2839 (Online) 
RENETA (4.113%), BEACONPHAR (2.369%), PHARMAID (0.575%) and BPL (0.033%) should be considered 
satisfactory. The lower ratios conclude that management should be more efficient in using the long term fund of 
owners and creditors. From the calculated value of t it is observed that there is a significant difference in return on 
capital employed between industry average and 4 individual pharmaceuticals firms (ACTIVEFINE, 
SQURPHARMA, BXPHARMA and BPL). For other pharmaceuticals the difference is insignificant. 
7.1.6 Return on Total Assets 
This ratio is calculated to measure the profit after the tax against the amount invested in total assets to ascertain 
whether assets are being utilized properly or not. Some authors consider 10% to 12% rate of return on total assets as 
reasonable norm for a profitable firms and this may be considered as reasonable norm for the selected enterprises. 
Table -06 shows that the average return on total assets ranges from 0.59% in BPL to 7.42% in SQURPHARMA and 
the average return on total assets for BXPHARMA is negative (-3.77%0. It is seen from the table that the average 
return on total assets is 1.83% which is far away from standard norm. The average returns on total assets of all 
pharmaceuticals are below the standard norm which cannot be considered as satisfactory and desirable. The average 
return on total assets of BEACONPHAR (0.70%), BXPHARMA (-3.77%), AMBEEPHA (1.28%) and BPL (0.59%) 
are below the industry average. The calculated ratios show a decreasing trend for most of the pharmaceuticals during 
the period of study and lower ratios indicate the assets were not being utilized properly during the period. In the 
context of variation of this ratio over the years, it is found that the variation is almost stable. The calculated values of 
t state that there is a significant difference in return on total assets between industry average and 4 individual 
pharmaceuticals firms (SQURPHARMA, BEACONPHAR, PHARMAID and BPL). For other pharmaceuticals the 
difference is insignificant. 
7.2 Liquidity Ratio 
The Current Ratio and Quick Ratio, Current Assets to Fixed Assets and Net Working Capital to Total Assets are 
used to assess liquidity position of an enterprise. The tables (07, 08, 09, and10) depict various financial ratios 
covering liquidity of the selected pharmaceuticals for the period under study. 
7.2.1 Current Ratio 
This ratio is a measure of the firm’s short term solvency of the firm’s liquidity. It indicates the ability of the 
company to meet its current obligations. If the current ratio is too low, the firm may have difficulty in meeting short 
run commitment as they measure. If the ratio is too high the firm may have an excessive investment in current assets 
or be under utilizing short term credit. Some authors consider 2:1 as standard norm for current ratio. Table-07 shows 
that the industry average current ratio is 0.94:1 which indicates that the industry is not able to meet its current 
obligations from its current assets. The average current ratio ranges from 0.57:1 in AMBEEPHA to 1.12:1 in 
SQURPHARMA. The average current ratios of BEACONPHAR (0.61:1), AMBEEPHA (0.57:1) and BPL (0.85:1) 
are below the industry average as well as below the standard norm. The average current ratios of ACTIVEFINE 
(1.08:1), SQURPHARMA (1.12:1), IBNSINA (1.10:1), BXPHARMA (1.06:1), RENETA (1.08:1) and 
PHARMAID (0.98:1) are above the industry average but below the standard norm. It is seen from the table that all 
these ratios are far from standard norm. Therefore it can be said that the liquidity in terms of current ratio had been 
quite inadequate in all the years under study for all the pharmaceuticals. The downward trend of current ratios of 
BXPHARMA, RENETA, BEACONPHAR, AMBEEPHA, PHARMAID and BPL indicate the inefficient liquidity 
management in case of the selected pharmaceuticals, the financial position is very unsatisfactory and the companies’ 
short term solvency is threatened. From the coefficient of variation it is clear that the variation of current ratio over 
time is negligible. From the calculated value of t it is seen that there is a significant difference in current ratio 
between industry average and 4 individual pharmaceuticals firms (RENETA, BEACONPHAR, AMBEEPHA, and 
PHARMAID). For other pharmaceuticals the difference is insignificant.  
7.2.2 Liquid (Quick or Acid Test) Ratio 
It measures the firm’s ability to meet short term obligations from its most liquid assets. Table-08 shows that the 
industry average of liquid ratio is 0.57:1 which is very lower than the standard (1:1) ratio. The table reveals that the 
average liquid ratio ranges from 0.29:1 in IBNSINA and in BEACONPHAR to 1.28:1 in ACTIVEFINE. The 
average liquid ratios of IBNSINA (0.29:1), RENETA (0.55:1), BEACONPHAR (0.29:1), AMBEEPHA (0.38:1) and 
BPL (0.43:1) are below the industry average as well as far away from standard norm and the average ratios of 
SQURPHARMA (0.64:1), BXPHARMA (0.59:1), and PHARMAID (0.70:1) are above the industry average but 
below the standard norm. It indicates that all pharmaceuticals except ACTIVEFINE (average liquid ratio is 1.28:1) 
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are financially very weak and have no ability to pay its most immediate liabilities. It is also observed that this 
position is declining for most of the pharmaceuticals and it is the dangerous signal for the companies. In the context 
of variation of this ratio over the years, it is found that the variation is almost stable. From the calculated value of t it 
is observed that there is a significant difference in liquid ratio between industry average and 4 individual 
pharmaceuticals firms (ACTIVEFINE, IBNSINA, BEACONPHAR and AMBEEPHA). For other pharmaceuticals 
the difference is insignificant. 
7.2.3 Current Assets to Fixed Assets 
Another criterion for liquidity assessment is the ratio between current assets to fixed assets. This ratio will differ 
from industry to industry and, therefore, no standard can be laid down. A decrease in ratio may mean that trading is 
slack or more mechanization has been put through. The table-09 shows that the industry average current asset to 
fixed assets is 0.78:1. It is seen from the table that the average current assets to fixed assets ratio ranges from 0.40:1 
in ACTIVEFINE to 1.06:1 in SQURPHARMA and the average ratio for ACTIVEFINE (0.40:1), IBNSINA (0.79:1), 
RENETA (0.51:1), BPL (0.61:1) is lower than industry average and the average ratio for SQURPHARMA (1.06:1), 
BXPHARMA(0.94:1), BEACONPHAR (0.89:1), AMBEEPHA (0.92:1) and PHARMAID (0.93:1) is higher than 
the industry average. The calculated ratios show a decreasing trend for some pharmaceuticals which mean that 
trading is slack or more mechanization has been put through in that pharmaceuticals. From the coefficient of 
variation it is clear that the variation of current ratio over time is negligible. From the calculated value of t it is 
observed that there is a significant difference in current assets to fixed assets between industry average and 
ACTIVEFINE. For all other pharmaceuticals the difference is insignificant.  
7.2.4 Net Working Capital to Total Assets 
Table-10 shows net working capital to total assets ratios for the selected pharmaceuticals for the study period. It is 
seen from the table that the industry average of net working capital to total assets ratio is -0099:1. The table reveals 
that the average net working capital to total assets ratios of ACTIVEFINE (0.0383), SQURPHARMA (0.0543), 
IBNSINA (0.0403), BXPHARMA (0.0247), RENETA (0.0247) and BPL (0.0407) are higher than industry average 
and the average ratio of BEACONPHAR (-0.2960), AMBEEPHA (-0.0004), PHARMAID (-0.0114), are lower than 
industry average and the figures are negative. From the calculated ratios it is clearly seen that the net working capital 
to total assets ratios are very small and for three pharmaceuticals the ratio is negative. Such state of affairs indicates 
the inability and inadequacy of net working capital to cover the total assets of the selected enterprise for the period 
under review. From the coefficient of variation it is seen that the variation of net working capital to total assets is 
insignificant. From the value of t it is observed that there is a significant difference in net working capital to total 
assets between industry average and 3 individual pharmaceuticals firms (RENETA, BEACONPHAR and 
AMBEEPHA). For other pharmaceuticals the difference is insignificant. 
7.3 Activity Ratios 
Activity ratios show the intensity with which the firm uses its assets in generation sales. These ratios indicate 
whether the firm’s investments in current and long-term assets are too small or too large. The objective is to have 
“enough” assets but not “too many”. The tables (11, 12, and13) depict various activity ratios of the selected 
pharmaceuticals for the period under study. 
7.3.1 Inventory Turnover Ratio 
This ratio is also known as stock turnover ratio, establishes relationship between sales (or cost of goods sold) and the 
total inventory (or average inventory). A low inventory turnover may indicate an excessive investment in inventories 
a high ratio often means that the firm is running out of stock, resulting in poor service to customers. It assists the 
financial manager in evaluating inventory policy to avoid any danger of over stocking as a prelude to the effective 
utilization of the resources of the firm. Higher the ratio the better it is because it shows that stock is rapidly turned 
over. The table-11 shows that the industry average inventory turnover is 6.45 times. It is seen from the table that the 
average inventory turnover ratio ranges from 1.47 times in BXPHARMA to 19.99 times in ACTIVEFINE. Some 
authors consider 8 to 9 times of inventory turnover ratio as the reasonable norm for an efficient concern. From the 
study it is seen that the average inventory turnover for all selected  pharmaceuticals except three pharmaceuticals, 
ACTIVEFINE(19.99 times), BEACONPHAR (9.52), PHARMAID (8.13), is lower than the industry average as well 
as standard norm which implies excessive inventory levels or a slow moving or obsolete inventories. If it is the 
obsolete inventories then it has to be written off. This will adversely affect the working capital and liquidity position 
of the firm. The calculated ratios indicate that the sale management of the selected pharmaceuticals can’t be said to 
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be efficient to sell its product. As to variation of inventory turnover over the years, it is revealed by the coefficient of 
variance that the coefficient of variance of 17.692% indicates inconsistency in the inventory turnover of 
BEAACONPHAR. The negligible variation of 0.675% in SQURPHARMA, 0.079% in IBNSINA, 0.086% in 
BXPHARMA, 2.141% in RENETA, 1.012% in AMBEEPHA, 5.889% in PHARMAID and 1.706% in BPL indicate 
extremely desirable stability position and with a variation of 8.689% in ACTIVEFINE shows a rather satisfactory 
stability position. The values of t state that there is a significant difference in inventory turnover between industry 
average and 4 individual pharmaceuticals firms (ACTIVEFINE, SQURPHARMA, IBNSINA and BXPHARMA). 
For other pharmaceuticals the difference is insignificant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
7.3.2 Net Fixed Assets Turnover 
The ratio indicates the extent of generating sales volume in terms of net fixed assets. Some authors consider that an 
ideal fixed assets turnover for an enterprise should be 5 times of net fixed assets and hence this may also be 
considered so far over selected case. Table-12 shows the net fixed assets turnover ratios for the selected 
pharmaceuticals for the study period. From the calculated ratios it is seen that the industry average net fixed assets 
turnover is 1.67 which is far away from the standard. The average ratio ranges from 0.58 times in BXPHARMA to 
4.41 times in BPL. The average ratio of ACTIVEFINE (1.17times), SQURPHARMA (1.41times), IBNSINA (1.16 
times), BXPHARMA (0.58times), RENETA (0.94 times) and AMBEEPHA (1.45 times) is lower than industry 
average as well as very lower than standard. Only three pharmaceuticals, BEACONPHAR (3.87 times), 
PHARMAID (2.02 times), BPL (4.41 times), have average ratio more than industry average but lower than standard. 
This low level of ratio indicates poor sales volume in terms of fixed assets. This indicates an inefficient use of fixed 
capital. From the coefficient of variation it is clear that the variations are very insignificant. From the calculated 
value of t it is observed that there is a significant difference in net fixed assets turnover between industry average 
and 5 individual pharmaceuticals firms (ACTIVEFINE, IBNSINA, BXPHARMA, RENETA and BEACONPHAR). 
For SQURPHARMA, AMBEEPHA, PHARMAID and BPL the difference is insignificant.  
7.3.3 Total Assets Turnover 
Another activity ratio is total assets turnover. This is a measure of the extent of generating sales in terms of the total 
assets. A standard norm of 200% (i.e. 2 times) of this ratio is considered norm by some authors for an industrial 
enterprise. This may also be taken as such for our selected pharmaceuticals. Table-13 reveals that the average total 
assets turnover ratio ranges from 0.30 times in BXPHARMA to 2.04 times in BEACONPHAR and the industry 
average is 0.90 times which is very lower than standard norm. It is seen from the table that the average ratio of 
ACTIVEFINE (0.81 times), SQURPHARMA (0.69 times), IBNSINA (0.65 times), BXPHARMA (0.30 times), 
RENETA (0.62 times) and AMBEEPHA (0.77 times) is lower than the industry average as well as standard norm, 
but the average ratio of BEACONPHAR (2.04 times) is higher than industry average as well as standard norm and 
the average ratio of PHARMAID (1.00 time), BPL (1.24 times) is higher than the industry average but lower than  
standard norm. Such a low level of total assets turnover ratio of ACTIVEFINE, SQURPHARMA, IBNSINA, 
BXPHARMA, RENETA and AMBEEPHA indicates that the selected  pharmaceuticals (ACTIVEFINE, 
SQURPHARMA, IBNSINA, BXPHARMA, RENETA, AMBEEPHA, PHARMAID and BPL generate lower taka 
of sales per taka of tangible assets which may be an indication of poor use of fixed and circulating capital. On the 
other hand the position is strong for BXPHARMA, BEACONPHAR. From the coefficient of variation it is seen that 
the variation over time is stable. From the calculated value of t it is observed that there is a significant difference in 
total assets turnover between industry average and 5 individual pharmaceuticals firms (SQURPHARMA, IBNSINA, 
BXPHARMA, RENETA and BEACONPHAR). For other pharmaceuticals the difference is insignificant. 
7.4 Solvency Ratios 
Debt-Equity ratio and Debt to Total Assets ratio are commonly used solvency ratios. The tables (14 and 15) depict 
various solvency ratios of the selected pharmaceuticals for the period under study. 
7.4.1 Debt-Equity Ratio 
Equity represents a “cushion” for share-holders. This is a ratio calculated to measure the relative proportions of 
outsiders’ funds and shareholder’ funds invested in the company. This ratio is also known as external-internal equity 
ratio. The standard ratio is 2:1. The table-14 shows the debt-equity ratio for the selected pharmaceuticals for the 
study period. It is revealed from the table that the average debt-equity ratio is 2.01:1. The debt-equity ratio ranges 
from 0.33:1 in ACTIVEFINE to 7.28:1 in AMBEEPHA. It is seen from the table that the average ratio of 
ACTIVEFINE (0.33:1), SQURPHARMA (1.08:1), IBNSINA (0.65:1), RENETA (1.24:1) and BPL (0.65:1) is lower 
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than the industry average as well as standard norm, but the average ratio of BXPHARMA (2.27:1), BEACONPHAR 
(3.19:1), AMBEEPHA (6.23:1) and PHARMAID (2.44:1) is higher than the industry average as well as standard 
norm. These low levels of debt-equity ratio of ACTIVEFINE, SQURPHARMA, IBNSINA, RENETA and BPL 
mean that the claims of creditors are lower than those of owners and the company has not liberally used debt to 
finance its assets. It indicates an inefficient financial management. On the other hand the position is strong for 
BXPHARMA, BEACONPHAR, AMBEEPHA and PHARMAID. From the coefficient of variance it is seen that the 
variations of ACTIVEFINE(0.001:1), SQURPHARMA(0.019:1), IBNSINA(0.007:1), BXPHARMA(0.047:1), 
RENETA(0.008:1), BEACONPHAR(0.241:1), AMBEEPHA(0.057:1), PHARMAID(0.063:1) and BPL(0.091:1) are 
very insignificant i.e. the variation is stable. From the calculated value of t it is seen that there is a significant 
difference in debt-equity ratio between industry average and 7 individual pharmaceuticals firms (ACTIVEFINE, 
SQURPHARMA, IBNSINA, RENETA, BEACONPHAR, AMBEEPHA and BPL). For other pharmaceuticals 
(BXPHARMA and PHARMAID) the difference is insignificant. 
7.4.2 Debt to Total Assets Ratio 
The objective of this ratio is to assign what portion of total assets (debt + equity) is collected from debt. Some 
authors consider that debt to total assets ratio should be 50% for an industrial enterprise. The table-15 shows the 
debt to total assets ratio for the selected pharmaceuticals for the study period. It is observed from the table that the 
industry average debt equity ratio is 36% which is lower than the standard norm. It is also seen from the table that 
the average ratio ranges from 7% in ACTIVEFINE to 83% in AMBEEPHA. The calculated ratios indicate the claim 
of creditors is about to very small in percentage to the shareholders of ACTIVEFINE (7%), SQURPHARMA (28%), 
IBNSINA (35%), RENETA (33%), and BEACONPHAR (24%), PHARMAID (27% 0 and BPL (13%) Such a lower 
ratio of debts to total assets of selected pharmaceuticals reveals the fact that they are less dependent on debt rather 
than on their own capital for financing their projects. On the other hand the average ratio of BXPHARMA (75%) 
and AMBEEPHA (83%) is higher than the average as well as the standard norm which indicates that BXPHARMA 
and AMBEEPHA are more dependent on debt rather than their own capital for financing project. From the 
coefficient of variation it is clear that the variation over time is very insignificant for all the selected 
pharmaceuticals. From the calculated value of t it is observed that there is a significant difference in debt to total 
assets between industry average and 6 individual pharmaceuticals firms (ACTIVEFINE, BXPHARMA, 
BEACONPHAR, AMBEEPHA, PHARMAID and BPL). For other pharmaceuticals the difference is insignificant. 
8. Testing financial soundness of sample Industry 
After examining liquidity, profitability and solvency of sample Industry, now it is necessary to examine the overall 
financial soundness of the selected pharmaceuticals during the study period. In this context Multivariate 
Discriminate Analysis (MDA) model as developed by Prof. Altman may be considered worth while. The said model 
can give some rough idea about the financial soundness of the selected industry. He developed the following 
equation for judging the financial soundness of an enterprise.  
Z = 0.012x1 + 0.014x2 + 0.033x3 + 0.006x4 + 0.999x5  
Where; 
           X1: Working Capital / Total Assets 
             X2: Retained earnings / Total Assets 
             X3: Earning before interest & taxes / Total Assets 
             X4: Market value of equity / Total debt 
             X5: Sales / Total Assets 
             Z: Overall index 
In order to test the overall financial soundness of the selected pharmaceuticals, it needs to calculate the ratios of 
working capital to total assets, retained earnings to total assets, earning before interest & taxes to total assets, market 
value of equity to book value of total debt and sales to total assets.  
The table-16 depicts the year wise as well as average position of the ratios of working capital to total assets, retained 
earnings to total assets, earning before interest and taxes to total assets, market value of equity to total debt and sales 
to total assets. 
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The year wise position of all these ratios excepting market value of equity to total debt had been either negative or to 
low positive. These resulted in poor financial performance of the sample pharmaceuticals during study period. It is 
seen from the table that the average positions of the working capital to total assets are 0.058, 0.174, 0.04, 0.021, 
0.025, (0.296), (0.0004), (0.012), (0.079) times, the retained earnings to total assets ratios are 0.012, 0.074, 0.007, 
(0.0370, (0.032), (0.344), 0.0103, 0.0045, 0.005 times, the earning before interest & taxes to total assets are 0.022, 
0.115, 0.092, 0.045, 0.156, 0.052, 0.123, 0.059, 0.024 times, the sales to total assets are 0.813, 0.687, 0.647, 0.299, 
0.62, 2.04, 0.749, 1.00, 1.227 times for  ACTIVEFINE , SQURPHAEMA , IBNSINA, BXPHARMA, RENETA, 
BEACONPHAR, AMBEEPHA, PHARMAID and BPL respectively. Such lower positions of these ratios indicate 
very unsatisfactory position. On the other hand the average market value of equity to total debt are 3.072, 0.94, 
1.547, 0.443, 0.813, 0.32, 0.138, 0.414, 1.767 times for  ACTIVEFINE , SQURPHARMA , IBNSINA, 
BXPHARMA, RENETA, BEACONPHAR, AMBEEPHA, PHARMAID and BPL  respectively which indicate 
unsatisfactory position of financial performance of the sample industry. From coefficient of variance it is clear that 
the variance over time is very insignificant for all the pharmaceuticals. 
The Table-17 shows the year-wise as well as average position of Z’s score of the sample pharmaceuticals during the 
study period. After putting the respective average values of x1, x2, x3, x4 and x5, in the aforesaid equations as 
developed by Prof. Altman, Z score was estimated. The average Z score ranges from 0.298 in BXPHARMA to 
2.033 in BEACONPHAR and the industry average Z score is 0.909 comparing with Prof. Altman’s conclusion that 
firms with Z score above 2.99 were solvent while those below Z score of 1.81 were bankrupt.  
Average Z score of sample pharmaceutical ACTIVEFINE (0.832), SQURPHARMA (0.735), IBNSINA (0.655), 
BXPHARMA (0.298), RENETA (0.633), AMBEEPHA (0.754) are lower than the industry average as well as the 
range provided by Prof. Altman. On the other hand average Z score of sample pharmaceuticals of PHARMAID 
(1.004) and BPL (1.243) are higher than the industry average but lower than the range provided by Prof. Altman. 
Only Z score of BEACONPHAR (2.033) exists within the range provided by Prof. Altman. The table shows the 
position of bankruptcy at a lower level during the period for all the selected pharmaceuticals except 
BEACONPHAR. 
It can be concluded that the overall financial soundness of the sample Industry during the study period had been 
worst leading to total bankruptcy of the industry. From the calculated value of t it is observed that there is a 
significant difference in Z score between industry average and 6 individual pharmaceuticals firms 
(SQURPHARMA, IBNSINA, BXPHARMA, RENETA, BEACONPHAR and AMBEEPHA). For other 
pharmaceuticals the difference is insignificant. 
9. Conclusions 
From the discussion it can be concluded that the financial position and operational performance of the most of the 
selected pharmaceuticals were not satisfactory. The inefficiency of financial management may be a major cause for 
such a poor position of the state of affairs. This view was also substantiated by using Prof. Altman’s MDA model. 
By applying this model it is seen that the overall financial position of the sample pharmaceuticals was at the lower 
level of bankruptcy except only one pharmaceuticals (BEACONPHAR). The main reasons attributed to such a 
situation were reported to be poor market demands, scarcity of raw materials, high competition, vanished quota 
system, management in attention, lack of realistic goals, strict government regulations, political instability, increased 
price of raw materials and others, adverse environmental factors etc. In order to save the pharmaceuticals from total 
bankruptcy the financial performance of the sample pharmaceuticals should be improved as early as possible. 
The followings are the recommendation from the researcher: 
i. The financial management specially purchase, sales and inventory management have to be motivated, so that 
they act all the tasks cordially, efficiently and honestly. 
ii. The Pharmaceuticals should regularly make use of ratio analysis and measure should be taken to improve 
undesirable ratios at least as to the point of industry’s average. 
iii. Qualified, trained and experienced management personnel should be appointed.  
iv. Government regulations should be flexible and policy should be realistic. 
v. Operational efficiency should be increased by reducing cost and wastage and improving operating and 
management performance. Supply of working capital should be adequate. 
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vi. Liquidity position of the selected Pharmaceuticals should be improved by reducing current liabilities. 
vii. Realistic goal should be set out. 
viii. A reasonable credit policy should be implemented, so that the main portion of profit does not spend in 
payment of fixed charges. 
ix. Accountability and motivation for achievement of performance and penalization for non-achievement of the 
same should be fixed up. 
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Table-01: Gross Profit Margin 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFINE 11 13.56 13.51 12.69 17.69 1.4638 2.143 -5.192* 0.027 
SQURPHARMA 22.13 22.84 16.87 20.61 17.69 3.2612 10.635 1.553 0.261 
IBNSINA 21.98 21.46 19.89 21.11 17.69 1.0881 1.184 5.444* 0.032 
BXPHARMA 39.03 29.18 35.08 34.43 17.69 4.9571 24.573 5.849* 0.028 
RENETA 9.62 10.12 11.82 10.52 17.69 1.1533 1.330 -10.768** 0.009 
BEACONPHAR 9.70 9.28 9.27 9.42 17.69 0.2454 0.060 -58.388** 0.000 
BEACONPHAR 18.44 19.90 22.57 20.30 17.69 2.0943 4.386 2.161 0.163 
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PHARMAID 14.16 14.25 14.32 14.24 17.69 0.0802 0.006 -74.429** 0.000 
BPL 16.22 16.23 15 15.82 17.69 0.7073 0.500 -4.588* 0.044 
Source: Annual Report and Official Records of the selected Pharmaceuticals  
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
(Insert the table after 7.1.1) 
Table-02: Net Profit Margin 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFINE 1.80 2.40 2.53 2.24 1.35 0.3894 0.152 3.974 0.058 
SQURPHARMA 13.31 11.13 7.83 10.75 1.35 2.7590 7.612 3.978 0.059 
IBNSINA 3.87 4.67 4.78 4.44 1.35 0.4967 0.247 10.775** 0.009 
BXPHARMA (4.01) (23.30) (12.79) (13.36) 1.35 9.6579 93.275 -20.639** 0.005 
RENETA 2.71 3.35 4.50 3.52 1.35 0.9070 0.823 4.544* 0.050 
BEACONPHAR 0.52 0.22 0.30 0.34 1.35 0.1553 0.024 -11.19** 0.008 
BEACONPHAR 0.97 0.96 2.28 1.40 1.35 0.7592 0.576 0.122 0.914 
PHARMAID 2.34 2.50 2.26 2.37 1.35 0.1222 0.015 14.410** 0.005 
BPL 0.72 0.52 0.20 0.48 1.35 0.2623 0.069 -5.624* 0.030 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
(Insert the table after 7.1.2) 
 
 
 
 
 
 
 
Table-03: Return on Investment 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFINE 2.57 2.93 3.09 2.86 6.67 0.2663 0.071 -24.756** 0.002 
SQURPHARMA 20.72 32.93 19.48 24.38 6.67 7.4333 55.254 4.126 0.054 
IBNSINA 11.79 15.73 15.64 14.39 6.67 2.2492 5.059 5.942* 0.027 
BXPHARMA (1.39) (6.74) (3.19) -3.77 6.67 2.7223 7.411 -6.645* 0.022 
RENETA 3.69 4.79 6.20 4.89 6.67 1.2582 1.583 -2.446 0.134 
BEACONPHAR 4.77 2.01 2.21 3.00 6.67 1.5390 2.369 -4.134 0.054 
BEACONPHAR 6.85 8.90 17.72 11.16 6.67 5.7757 33.359 1.345 0.311 
PHARMAID 2.27 2.35 2.45 2.36 6.67 0.0902 0.008 -82.84** 0.000 
BPL 0.75 0.76 0.70 0.74 6.67 0.0321 0.001 -319.69** 0.000 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
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*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
(Insert the table after 7.1.3) 
 
Table-04: Operating Profit Ratio 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFINE 3.92 5.27 5.32 4.84 10.72 0.7943 0.631 -12.83** 0.006 
SQURPHARMA 19.63 20.89 14.78 18.43 10.72 3.2260 10.407 4.141 0.054 
IBNSINA 18.09 16.47 15.18 16.58 10.72 1.4581 2.126 6.961* 0.020 
BXPHARMA 29.61 23.34 34.11 29.02 10.72 5.4092 29.259 5.860* 0.028 
RENETA 2.99 4.02 5.55 4.19 10.72 1.2881 1.659 -8.785* 0.013 
BEACONPHAR 0.61 0.26 0.35 0.41 10.72 0.1818 0.033 -98.284** 0.000 
BEACONPHAR 14.10 16.01 17.87 15.99 10.72 1.8851 3.553 4.845* 0.040 
PHARMAID 2.85 3.05 2.35 2.75 10.72 0.3606 0.130 -38.287** 0.001 
BPL 4.23 3.35 4.78 4.12 10.72 0.7213 0.520 -15.848** 0.004 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
(Insert the table after 7.1.4) 
 
 
 
 
 
 
 
 
Table-05: Return on Capital Employed 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFINE 2.03 2.32 2.45 2.27 3.59 0.2150 0.046 -10.66** 0.009 
SQURPHARMA 15.02 15.69 10.65 13.79 3.59 2.7370 7.491 6.453* 0.023 
IBNSINA 3.70 5.01 5.60 4.77 3.59 0.9725 0.946 2.102 0.170 
BXPHARMA (2.32) (14.9) (5.35) (7.52) 3.59 6.5656 43.107 -5.932* 0.039 
RENETA 0.35 3.09 4.31 2.58 3.59 2.0280 4.113 -0.860 0.481 
BEACONPHAR 4.77 2.01 2.21 3.00 3.59 1.5390 2.369 -0.668 0.573 
BEACONPHAR 4.06 4.92 13.62 7.53 3.59 5.2887 27.971 1.291 0.326 
PHARMAID 3.70 4.33 5.21 4.41 3.59 0.7584 0.575 1.880 0.201 
BPL 1.53 1.59 1.25 1.46 3.59 0.1815 0.033 -20.361** 0.002 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
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(Insert the table after 7.1.5) 
 
Table-06: Return on Total Assets 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFINE 1.61 1.88 2.01 1.83 1.83 0.2040 0.042 0.028 0.980 
SQURPHARMA 9.00 8.27 5.00 7.42 1.83 2.1302 4.538 4.548* 0.045 
IBNSINA 2.31 3.11 3.20 2.87 1.83 0.4899 0.240 3.688 0.066 
BXPHARMA (1.39) (6.74) (3.19) (3.77) 1.83 2.7223 7.411 -3.565 0.070 
RENETA 2.23 3.09 4.31 3.21 1.83 1.0452 1.092 2.287 0.149 
BEACONPHAR 1.04 0.46 0.61 0.70 1.83 0.3011 0.091 -6.482* 0.023 
BEACONPHAR 0.82 1.02 2.00 1.28 1.83 0.6315 0.399 -1.509 0.270 
PHARMAID 2.12 2.26 2.45 2.28 1.83 0.1656 0.027 4.671* 0.043 
BPL 0.75 0.76 0.25 0.59 1.83 0.2916 0.085 -7.385* 0.018 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
(Insert the table after 7.1.6) 
 
 
 
 
 
 
 
 
Table-07: Current Ratio 
Name of the 
Pharmaceuticals 
2005-
06 
2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFINE 1.26:1 1.51:1 1.74:1 1.08:1 0.94:1 0.241 0.058 4.064 0.056 
SQURPHARMA 1.05:1 1.09:1 1.21:1 1.12:1 0.94:1 0.083 0.007 3.675 0.067 
IBNSINA 0.98:1 1.13:1 1.19:1 1.10:1 0.94:1 0.108 0.012 2.562 0.125 
BXPHARMA 1.27:1 0.98:1 0.92:1 1.06:1 0.94:1 0.187 0.035 1.080 0.393 
RENETA 1.09:1 1.08:1 1.06:1 1.08:1 0.94:1 0.015 0.001 15.497** 0.004 
BEACONPHAR 0.70:1 0.60:1 0.52:1 0.61:1 0.94:1 0.090 0.008 -6.402* 0.024 
BEACONPHAR 0.58:1 0.56:1 0.56:1 0.57:1 0.94:1 0.012 0.001 -56.00** 0.000 
PHARMAID 0.98:1 0.97:1 0.98:1 0.98:1 0.94:1 0.006 0.001 11.00** 0.008 
BPL 0.98:1 0.90:1 0.67:1 0.85:1 0.94:1 0.161 0.026 -0.969 0.435 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
(Insert the table after 7.2.1) 
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Table-08: Liquid/ Quick/ Acid Test Ratio 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed
) 
ACTIVEFINE 1.06:1 1.31:1 1.47:1 1.28:1 0.57:1 0.207 0.043 5.951* 0.027 
SQURPHARMA 0.58:1 0.66:1 0.69:1 0.64:1 0.57:1 0.057 0.003 2.234 0.155 
IBNSINA 0.35:1 0.34:1 0.18:1 0.29:1 0.57:1 0.096 0.009 -5.084* 0.037 
BXPHARMA 0.68:1 0.52:1 0.57:1 0.59:1 0.57:1 0.082 0.007 0.423 0.713 
RENETA 0.51:1 0.66:1 0.49:1 0.55:1 0.57:1 0.093 0.009 -0.311 0.783 
BEACONPHAR 0.32:1 0.23:1 0.33:1 0.29:1 0.57:1 0.055 0.003 -8.701* 0.013 
BEACONPHAR 0.42:1 0.37:1 0.34:1 0.38:1 0.57:1 0.040 0.002 -8.286* 0.014 
PHARMAID 0.59:1 0.76:1 0.74:1 0.70:1 0.57:1 0.093 0.009 2.361 0.142 
BPL 0.47:1 0.50:1 0.32:1 0.43:1 0.57:1 0.096 0.009 -2.514 0.128 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
(Insert the table after 7.2.2) 
 
 
 
 
 
 
 
STable-09: Current Assets to Fixed Assets 
Name of the 
Pharmaceuticals 
2005-
06 
2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFINE 0.35:1 0.40:1 0.46:1 0.40:1 0.78:1 0.055 0.003 -11.846** 0.007 
SQURPHARMA 0.66:1 0.96:1 1.56:1 1.06:1 0.78:1 0.458 0.211 1.058 0.401 
IBNSINA 0.58:1 0.74:1 1.04:1 0.79:1 0.78:1 0.234 0.055 0.049 0.965 
BXPHARMA 1.04:1 1.16:1 0.61:1 0.94:1 0.78:1 0.289 0.084 0.938 0.447 
RENETA 0.44:1 0.43:1 0.66:1 0.51:1 0.78:1 0.130 0.017 -3.597 0.069 
BEACONPHAR 1.22:1 0.85:1 0.60:1 0.89:1 0.78:1 0.312 0.098 0.611 0.604 
BEACONPHAR 0.82:1 0.90:1 1.03:1 0.92:1 0.78:1 0.106 0.011 2.233 0.155 
PHARMAID 0.79:1 0.90:1 1.09:1 0.93:1 0.78:1 0.152 0.023 1.674 0.236 
BPL 0.50:1 0.74:1 0.60:1 0.61:1 0.78:1 0.121 0.015 -2.395 0.139 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
(Insert the table after 7.2.3) 
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Table-10: Net Working Capital to Total Assets 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFINE (0.005) 0.04 0.08 0.0383 (0.0099) 0.0425 0.002 1.965 0.188 
SQURPHARMA 0.019 0.04 0.104 0.0543 (0.0099) 0.0443 0.002 2.513 0.129 
IBNSINA (0.006) 0.047 0.080 0.0403 (0.0099) 0.0434 0.002 2.006 0.183 
BXPHARMA 0.018 (0.012) (0.035) 0.0203 (0.0099) 0.0266 0.001 0.020 0.986 
RENETA 0.026 0.024 0.024 0.0247 (0.0099) 0.0012 0.000 54.684** 0.000 
BEACONPHAR (0.233) (0.307) (0.348) (0.2960) (0.0099) 0.0583 0.003 -8.508* 0.014 
BEACONPHAR (0.0003) (0.0004) (0.0004) (0.0004) (0.0099) 0.0001 0.000 4.465* 0.050 
PHARMAID (0.008) (0.0140) (0.0122) (0.0114) (0.0099) 0.0031 0.000 -0.821 0.498 
BPL (0.008) (0.05) 0.18 0.0407 (0.0099) 0.1225 0.015 0.716 0.548 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
(Insert the table after 7.2.4) 
 
 
 
 
 
 
 
 
Table-11: Inventory Turnover 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFINE 22.30 21.00 16.67 19.99 6.45 2.9478 8.689 7.956* 0.015 
SQURPHARMA 4.09 4.26 2.76 3.70 6.45 0.8214 0.675 -5.792* 0.029 
IBNSINA 1.66 2.09 1.56 1.77 6.45 0.2816 0.079 -28.785** 0.001 
BXPHARMA 1.52 1.16 1.74 1.47 6.45 0.2928 0.086 -29.439** 0.001 
RENETA 3.64 5.64 2.79 4.03 6.45 1.4632 2.141 -2.873 0.103 
BEACONPHAR 6.75 7.45 14.36 9.52 6.45 4.2062 17.692 1.264 0.334 
BEACONPHAR 3.82 5.70 4.14 4.55 6.45 1.0058 1.012 -3.266 0.082 
PHARMAID 5.44 8.81 10.15 8.13 6.45 2.4268 5.889 1.201 0.353 
BPL 3.35 5.67 5.55 4.86 6.45 1.3062 1.706 -2.113 0.169 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
(Insert the table after 7.3.1) 
 
Table-12: Net Fixed Assets Turnover 
European Journal of Business and Management   www.iiste.org 
ISSN 2222-1905 (Paper) ISSN 2222-2839 (Online) 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFINE 1.22 1.12 1.17 1.17 1.67 0.0500 0.003 -17.321** 0.003 
SQURPHARMA 1.13 1.45 1.64 1.41 1.67 0.2577 0.066 -1.770 0.219 
IBNSINA 0.95 1.16 1.36 1.16 1.67 0.2050 0.042 -4.337* 0.049 
BXPHARMA 0.71 0.63 0.40 0.58 1.67 0.1609 0.026 -11.731** 0.007 
RENETA 0.86 0.96 1.00 0.94 1.67 0.0721 0.005 -17.534** 0.003 
BEACONPHAR 4.43 3.96 3.23 3.87 1.67 0.6047 0.366 6.311* 0.024 
BEACONPHAR 1.29 1.56 1.51 1.45 1.67 0.1436 0.021 -2.613 0.121 
PHARMAID 1.72 1.71 2.63 2.02 1.67 0.5283 0.279 1.147 0.370 
BPL 2.34 2.87 2.03 4.41 1.67 0.4248 0.180 3.031 0.094 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
(Insert the table after 7.3.2) 
 
 
 
 
 
 
 
 
Table-13: Total Assets Turnover 
Name of the  
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFINE 0.89 0.76 0.79 0.81 0.90 0.0681 0.005 -2.205 0.158 
SQURPHARMA 0.68 0.74 0.64 0.69 0.90 0.0503 0.003 -7.341* 0.018 
IBNSINA 0.60 0.67 0.67 0.65 0.90 0.0404 0.002 -10.857** 0.008 
BXPHARMA 0.35 0.29 0.25 0.30 0.90 0.0503 0.003 -20.762** 0.002 
RENETA 0.59 0.67 0.60 0.62 0.90 0.0436 0.002 -11.126** 0.008 
BEACONPHAR 1.99 2.13 2.00 2.04 0.90 0.0781 0.006 25.281** 0.002 
BEACONPHAR 0.72 0.84 0.74 0.77 0.90 0.0643 0.004 -3.592 0.070 
PHARMAID 0.90 0.87 1.23 1.00 0.90 0.1997 0.040 0.867 0.477 
BPL 1.04 1.40 1.27 1.24 0.90 0.1823 0.033 3.199 0.085 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
(Insert the table after 7.3.3) 
 
Table-14: Debt-Equity Ratio 
Name of the 2005-06 2006-07 2007-08 Mean Industry S.D C.V t value Sig.(2 
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Pharmaceuticals Mean tailed) 
ACTIVEFINE 0.35 0.32 0.31 0.33 2.01 0.021 0.001 -140.062** 0.000 
SQURPHARMA 1.14 1.18 0.92 1.08 2.01 0.140 0.019 -11.506** 0.007 
IBNSINA 0.60 0.61 0.75 0.65 2.01 0.084 0.007 -28.019** 0.001 
BXPHARMA 2.03 2.45 2.33 2.27 2.01 0.216 0.047 2.082 0.173 
RENETA 1.29 1.14 1.29 1.24 2.01 0.087 0.008 -15.400** 0.004 
BEACONPHAR 3.59 3.33 2.64 3.19 2.01 0.491 0.241 4.151* 0.053 
BEACONPHAR 6.97 7.44 7.28 7.23 2.01 0.239 0.057 37.837** 0.001 
PHARMAID 2.21 2.48 2.71 2.44 2.01 0.251 0.063 3.161 0.087 
BPL 0.39 0.58 0.98 0.65 2.01 0.301 0.091 -7.822* 0.016 
Source: Annual Report and Official Records of the selected Pharmaceuticals  
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
 (Insert the table after 7.4.1) 
 
 
 
 
 
 
 
 
Table-15: Debt to Total Assets Ratio 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFINE 0.08 0.07 0.06 0.07 0.36 0.0100 0.000 50.229** 0.000 
SQURPHARMA 0.30 0.31 0.24 0.28 0.36 0.0379 0.001 -3.507 0.073 
IBNSINA 0.35 0.36 0.34 0.35 0.36 0.0100 0.000 -1.732 0.225 
BXPHARMA 0.74 0.76 0.74 0.75 0.36 0.0115 0.000 58.00** 0.000 
RENETA 0.36 0.33 0.30 0.33 0.36 0.0300 0.001 -1.732 0.225 
BEACONPHAR 0.20 0.25 0.27 0.24 0.36 0.0361 0.001 -5.765* 0.029 
BEACONPHAR 0.82 0.83 0.83 0.83 0.36 0.0058 0.000 140.00** 0.000 
PHARMAID 0.30 0.27 0.24 0.27 0.36 0.0300 0.001 -5.196* 0.035 
BPL 0.13 0.17 0.10 0.13 0.36 0.0351 0.001 -11.179** 0.008 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
(Insert the table after 7.4.2) 
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Table: 16 (Ratios for Testing Financial Soundness) 
Ratios ACTI
VEFIN
E 
SQU
RPH
ARM
A 
IBNS
INA 
BXPH
ARM
A 
RENET
A 
BEACO
NPHAR 
AMBEEP
HA 
BEACONP
HAR 
PHARMA
ID 
BPL Year 
Working 
Capital to 
Total 
Assets (in 
time) 
(0.005) 
0.040 
0.080 
0.038 
0.042 
0.002 
0.019 
0.401 
0.104 
0.174 
0.200 
0.040 
(0.00
7) 
0.047 
0.080 
0.04 
0.044 
0.002 
0.108 
(0.012) 
(0.035) 
0.021 
0.077 
0.006 
0.026 
0.024 
0.024 
0.025 
0.001 
0.000 
(0.233) 
(0.307) 
(0.348) 
(0.296) 
0.0583 
0.0034 
(0.0003) 
(0.0004) 
(0.0004) 
(0.0004) 
0.00001 
0.00000 
(0.008) 
(0.014) 
(0.012) 
(0.012) 
0.0031 
0.0000 
(0.008) 
(0.05) 
(0.18) 
(0.079) 
0.0897 
0.0081 
2005-06 
2006-07 
207-08 
Mean 
S. D. 
C. V. 
Retained 
Earnings to 
Total 
Assets  (in 
time) 
0.007 
0.012 
0.017 
0.012 
0.005 
0.000 
0.09 
0.083 
0.050 
0.074 
0.021 
0.001 
0.016 
0.001 
0.003 
0.007 
0.008 
0.000 
(0.014) 
(0.067) 
(0.032) 
(0.037) 
0.027 
0.001 
(0.039) 
(0.036) 
(0.022) 
(0.032) 
0.009 
0.000 
(0.314) 
(0.329) 
(0.390) 
(0.344) 
0.041 
0.002 
0.0067 
0.0079 
0.0164 
0.0103 
0.0053 
0.0000 
0.0028 
0.0052 
0.0056 
0.0045 
0.0015 
0.0000 
0.008 
0.006 
0.002 
0.005 
0.003 
0.000 
2005-06 
2006-07 
207-08 
Mean 
S. D. 
C. V. 
Earning 
before 
interest and 
taxes to 
0.019 
0.022 
0.024 
0.124 
0.129 
0.092 
0.078 
0.103 
0.095 
0.077 
0.024 
0.036 
0.37 
0.047 
0.051 
0.048 
0.050 
0.057 
0.099 
0.132 
0.137 
0.046 
0.067 
0.064 
0.030 
0.034 
0.008 
2005-06 
2006-07 
207-08 
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Total 
Assets (in 
time) 
0.022 
0.003 
0.000 
0.115 
0.020 
0.001 
0.092 
0.013 
0.000 
0.045 
0.028 
0.001 
0.156 
0.185 
0.342 
0.052 
0.005 
0.000 
0.123 
0.021 
0.001 
0.059 
0.011 
0.000 
0.024 
0.014 
0.000 
Mean 
S. D. 
C. V. 
Market 
value of 
equity to 
Total Debt 
(in time)  
2.86 
3.125 
3.23 
3.072 
0.191 
0.037 
0.88 
0.85 
1.09 
0.94 
0.131 
0.017 
1.67 
1.64 
1.33 
1.547 
0.188 
0.035 
0.49 
0.41 
0.43 
0.443 
0.042 
0.002 
0.78 
0.88 
0.78 
0.813 
0.058 
0.003 
0.28 
0.30 
0.38 
0.32 
0.053 
0.003 
0.143 
0.134 
0.137 
0.138 
0.005 
0.000 
0.471 
0.403 
0.369 
0.414 
0.052 
0.003 
2.56 
1.72 
1.02 
1.767 
0.771 
0.594 
2005-06 
2006-07 
207-08 
Mean 
S. D. 
C. V. 
Sales to 
Total Asset 
(in time) 
0.89 
0.76 
0.79 
0.813 
0.068 
0.005 
0.68 
0.74 
0.64 
0.687 
0.050 
0.003 
0.59 
0.68 
0.67 
0.647 
0.049 
0.002 
0.35 
0.29 
0.25 
0.297 
0.050 
0.003 
0.59 
0.67 
0.60 
0.62 
0.043 
0.002 
1.99 
2.13 
2.00 
2.04 
0.078 
0.006 
0.709 
0.819 
0.721 
0.749 
0.060 
0.004 
0.90 
0.87 
1.23 
1.00 
0.199 
0.040 
1.04 
1.40 
1.24 
1.227 
0.180 
0.032 
2005-06 
2006-07 
207-08 
Mean 
S. D. 
C. V. 
 
Source: Annual Report and Official Records of the selected Pharmaceuticals industry, (2005-2008) 
(Insert the table after 8) 
 
Table: 17 (Analysis of Z score) 
Name of the 
Pharmaceuticals 
2005-06 2006-
07 
2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFINE 0.907 0.779 0.810 0.832 0.909 0.067 0.005 -1.997 0.184 
SQURPHARMA 0.690 0.754 0.761 0.735 0.909 0.039 0.002 -7.702* 0.016 
IBNSINA 0.602 0.683 0.680 0.655 0.909 0.046 0.002 -9.580* 0.011 
BXPHARMA 0.354 0.290 0.251 0.298 0.909 0.052 0.003 -20.789** 0.002 
RENETA 0.606 0.676 0.610 0.633 0.909 0.039 0.002 -12.264** 0.007 
BEACONPHAR 1.986 2.122 1.992 2.033 0.909 0.077 0.006 25.342** 0.002 
BEACONPHAR 0.713 0.823 0.726 0.754 0.909 0.060 0.004 -4.466* 0.047 
PHARMAID 0.903 0.876 1.233 1.004 0.909 0.199 0.039 0.828 0.495 
BPL 1.065 1.414 1.240 1.243 0.909 0.175 0.031 3.282 0.082 
 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
(Insert the table after 8 with table-16) 
 
Table: 18 List of Pharmaceuticals under study: 
 
Name of the Pharmaceuticals Short name used 
Active Fine Chemicals Limited ACTIVEFINE 
Square Pharmaceuticals Limited SQURPHARMA 
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The Ibn Sina Pharmaceuticals ltd. IBNSINA 
Beximco Pharma BXPHARMA 
Renata Ltd. RENATA 
Beasel Pharmaceuticals Limited BEACONPHAR 
Ambee Pharma AMBEEPHA 
Pharma Aids PHARMAID 
Beacon Pharmaceuticals Limited BPL 
(Insert the table after references) 
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